Business Wire

SMOKE-FREE-SWEDEN

Share
Landmark Report Proves That High Nicotine Use Does Not Lead to High Rates of Health Issues

A new report released today in Stockholm by international health experts, "No Smoke, Less Harm" presents compelling evidence that despite similar levels of nicotine consumption, Sweden boasts significantly lower rates of tobacco-related diseases compared with other European nations.

The report, which was unveiled during an event organised by Smoke Free Sweden, a global health advocacy group, details rates of nicotine usage in Sweden and a number of comparable countries, finding that nicotine use was not a factor in tobacco-related disease.

Furthermore, the report provided further evidence that what does affect consumers’ health is the method of consumption. While using alternative products such as snus did not pose a significant risk, smoking is linked with a high incidence of death and disease.

While nicotine consumption in Sweden mirrors the European average, the country reports a 41% lower incidence of lung cancer and fewer than half the tobacco-related deaths of its European peers. This stark contrast is attributed to the widespread adoption of smoke free nicotine products such as snus, nicotine pouches and electronic cigarettes.

“This distinction between smoking and the use of smokeless products is crucial,” says Dr. Karl Fagerström, a public health expert and contributor to the report.

“While nicotine is addictive, it does not cause the serious diseases associated with smoking. Our findings support a shift in focus from cessation to substitution with less harmful alternatives for those unable to stop completely.”

Sweden’s proactive measures in public health education and regulatory frameworks have encouraged a transition to these alternatives, significantly impacting public health outcomes. The report points out that embracing similar harm reduction strategies could be pivotal for other nations striving to reduce the health impacts of tobacco.

Dr. Fagerström added, "The Swedish experience demonstrates that understanding and addressing public misperceptions about nicotine can lead to health policies that better protect and inform consumers."

Notes to editors

The full report is available online at www.smokefreesweden.org - an executive summary is available at the following link (https://smokefreesweden.org/Executive%20Summary%20No%20Smoke%20Less%20Harm.pdf) and offers a detailed analysis of the data supporting Sweden’s health outcomes, along with recommendations for policymakers looking to adopt similar approaches in their countries.

About Smoke Free Sweden

Smoke Free Sweden is a movement that encourages other countries to follow the Swedish experience when it comes to Tobacco Harm Reduction. Sweden is about to become the first ‘smoke free’ European country, with a smoking rate of below five percent. This remarkable achievement can be attributed to Sweden’s open attitude towards alternative products.

For more information on Sweden’s successful approach to becoming a smoke free nation, please visit www.smokefreesweden.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507966074/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 08:30:00 CET | Press release

The GDC, established in LTTS’ Mobility segment, will strengthen PALFINGER’s localization roadmap and next-gen digital transformation initiatives L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, E

New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 08:10:00 CET | Press release

Cinemo and Futuresource Consulting’s research indicates consumer readiness for integrated audio environments, accelerating the shift from connected devices to a connected lifestyle. Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual

NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release

NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release

Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye